Cephalexin

Generic Name
Cephalexin
Brand Names
Keflex
Drug Type
Small Molecule
Chemical Formula
C16H17N3O4S
CAS Number
15686-71-2
Unique Ingredient Identifier
5SFF1W6677
Background

Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cephalexin was approved by the FDA on 4 January 1971.

Indication

Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria. These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.

Associated Conditions
Bone Infection, Genitourinary tract infection, Otitis Media (OM), Respiratory Tract Infections (RTI), Skin and skin structure infections, Acute Prostatitis
Associated Therapies
-
Clinical Trials
Related News

A Study of Cephalexin Capsules in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Cephalexin
First Posted Date
2014-04-25
Last Posted Date
2015-07-15
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
28
Registration Number
NCT02123446
Locations
🇲🇽

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico

A Study of Cephalexin Suspension in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Cephalexin
First Posted Date
2014-04-25
Last Posted Date
2015-05-27
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
28
Registration Number
NCT02123459
Locations
🇲🇽

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico

A Study of Cephalexin in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Cephalexin
First Posted Date
2014-04-01
Last Posted Date
2015-05-27
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
28
Registration Number
NCT02100826
Locations
🇲🇽

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

First Posted Date
2013-12-18
Last Posted Date
2024-12-03
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
265
Registration Number
NCT02014558
Locations
🇺🇸

Site US10018, Hershey, Pennsylvania, United States

🇺🇸

Site US10015, Chicago, Illinois, United States

🇺🇸

Site US10020, Hackensack, New Jersey, United States

and more 23 locations

The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery

Phase 4
Recruiting
Conditions
Facial Defect
Interventions
Drug: cephalexin
First Posted Date
2013-07-31
Last Posted Date
2024-04-03
Lead Sponsor
University of Michigan
Target Recruit Count
300
Registration Number
NCT01912651
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Effects of Treatments on Atopic Dermatitis

First Posted Date
2012-06-29
Last Posted Date
2024-12-17
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Target Recruit Count
130
Registration Number
NCT01631617
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

First Posted Date
2012-05-10
Last Posted Date
2020-08-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
717
Registration Number
NCT01595529
Locations
🇺🇸

Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric, Pittsburgh, Pennsylvania, United States

Antibiotic Prophylaxis Before Surgery Versus After Cord Clamping in Elective Cesarean Delivery - a Double-blind, Prospective, Randomized Placebo-controlled Trial

Not Applicable
Completed
Conditions
Elective Cesarean Section
Interventions
Drug: saline solution
Drug: Keflex
First Posted Date
2010-11-25
Last Posted Date
2010-11-25
Lead Sponsor
Medical University of Vienna
Target Recruit Count
1112
Registration Number
NCT01248078
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Antibiotic Prophylaxis for Simple Hand Lacerations

Not Applicable
Terminated
Conditions
Simple Hand Lacerations
Interventions
Drug: cephalexin
Drug: placebo
Drug: clindamycin
First Posted Date
2010-07-01
Last Posted Date
2014-11-07
Lead Sponsor
State University of New York - Downstate Medical Center
Target Recruit Count
73
Registration Number
NCT01155154
Locations
🇺🇸

Kings County Hospital Center, Brooklyn, New York, United States

🇺🇸

Staten Island University Hospital, Staten Island, New York, United States

🇺🇸

State University of New York, Downstate Medical Center, Brooklyn, New York, United States

Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip

Not Applicable
Terminated
Conditions
Through-and-through Lip Lacerations
Interventions
Drug: placebo
Drug: keflex
First Posted Date
2009-08-12
Last Posted Date
2019-04-16
Lead Sponsor
University of Pennsylvania
Target Recruit Count
4
Registration Number
NCT00957827
Locations
🇺🇸

Hopital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy